Enalkiren
Alternative Names: A 64662Latest Information Update: 24 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Antiglaucomas; Antihypertensives; Dipeptides; Heart failure therapies
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Heart failure; Hypertension
Most Recent Events
- 31 Jul 2004 Discontinued - Preclinical for Glaucoma in USA (Topical)
- 02 Jul 2001 No-Development-Reported for Glaucoma in USA (Topical)
- 30 Nov 2000 Discontinued for Heart failure in USA (unspecified route)